Coeptis Therapeutics Inc Stock Price, News & Analysis

Coeptis Therapeutics Holdings (NASDAQ: COEP) has announced the acquisition of the NexGenAI Affiliates Network platform and launched Coeptis Technologies, marking a strategic expansion into AI-powered solutions. The platform, developed by NexGenAI Solutions Group, provides AI-powered marketing software and robotic process automation (RPA) capabilities designed for the biotech, pharmaceutical, and multi-level marketing industries.

The acquisition aims to enhance marketing optimization, customer engagement, and operational efficiency in highly regulated sectors. The company views this integration as a strategic move to leverage advanced technologies within the biopharmaceutical sector and provide innovative tools for companies facing marketing challenges in competitive industries.

Coeptis Therapeutics Holdings (NASDAQ: COEP) has announced the launch of Coeptis Technologies, a new division aimed at diversifying its business beyond biopharmaceuticals. The company has signed a binding Letter of Intent to acquire key assets from a Risk Mitigation Software Company with 10,000 customers across 100 countries.

The acquisition includes proprietary technologies such as Data Placement Manager and Sensitive Content Manager solutions. This move follows the upcoming acquisition of NexGenAI Affiliates Network, positioning Coeptis in the data security and AI technology sectors. The Risk Mitigation Software Company's CEO will join Coeptis to lead the new technology division, with the transaction expected to close in early 2025.

Coeptis Therapeutics Holdings (Nasdaq: COEP) has executed a Binding Letter of Intent to acquire NexGenAI Affiliates Network, a platform offering AI-powered marketing software and robotic process automation (RPA) capabilities. The acquisition aims to enhance Coeptis's operational efficiency while maintaining its focus on biopharmaceutical innovation. NexGenAI's suite of marketing tools utilizes AI and RPA to optimize campaigns, streamline workflows, and generate insights, particularly targeting the biotech, pharmaceutical, and multi-level marketing industries. The platform helps companies manage marketing campaigns while maintaining regulatory compliance.

Coeptis Therapeutics announced the acceptance of Phase 1 study results for DVX201, an allogeneic natural killer (NK) cell therapy, in Molecular Therapy Methods and Clinical Development. The study evaluated DVX201 for treating hospitalized COVID-19 patients at high risk for disease progression. Key findings showed DVX201 was safe and well-tolerated in 9 patients, with no dose-limiting toxicities or cytokine release syndrome. The therapy, derived from pooled donor cord blood CD34+ cells, demonstrated rapid improvements in oxygenation, improved pulmonary radiographic findings, and led to hospital discharge within days of infusion.

Coeptis Therapeutics Holdings (Nasdaq: COEP) has expanded its license agreement with Deverra Therapeutics to include pandemic preparedness and emergency use applications for their allogeneic natural killer (NK) cell technology. The expanded license now covers the use of unmodified NK cells for treating viral infections, pandemic-related illnesses, and emergency stockpiling. This builds upon their August 2023 agreement, which included an allogeneic stem cell expansion platform, two IND applications, and two Phase 1 clinical trials investigating DVX201 as an unmodified NK cell therapy.

Coeptis Therapeutics Holdings, Inc. (Nasdaq: COEP), a biopharmaceutical company developing innovative cell therapy platforms, announced that its Chief Scientific and Medical Officer, Dr. Colleen Delaney, will present at several upcoming fall conferences. These events include:

• 2024 AABB Annual Meeting (October 19-22, Houston, TX)
• ASHI 50th Annual Meeting (October 21-24, Anaheim, CA)
• Advanced Therapies USA Congress (November 12-13, Philadelphia, PA)
• Donor Selection & Cell Source Summit (November 18-20, San Diego, CA)

The conferences provide an opportunity to showcase Coeptis' advancements in universal cell therapy for cancer, autoimmune, and infectious diseases. CEO Dave Mehalick emphasized the importance of these events in building momentum for their work on off-the-shelf universal allogeneic therapies, which aim to revolutionize cell therapy by lowering treatment costs and improving access to life-saving treatments.

Coeptis Therapeutics Holdings, Inc. (Nasdaq: COEP) has received a notification from the Nasdaq Hearings Panel granting continued listing on The Nasdaq Stock Market until January 15, 2025. This extension is subject to the company demonstrating compliance with the minimum bid price requirement of $1.00 per share. COEP had previously received a non-compliance notice on January 29, 2024, due to its stock price falling below $1.00 for 30 consecutive business days. The company presented a plan to address this issue, including a potential reverse stock split, to the Panel on September 12th. CEO Dave Mehalick expressed satisfaction with the decision and reaffirmed the company's commitment to regaining compliance and focusing on improving patient outcomes.

Coeptis Therapeutics Holdings, Inc. (Nasdaq: COEP) has issued a shareholder letter outlining recent updates and strategic vision. Key points include:

1. Completion of Phase 1 clinical trials for DVX201, an allogeneic NK cell therapy, in COVID-19 and AML/MDS patients.

2. Successful capital raise of $5.6 million through Series A preferred stock offering.

3. Expansion of SNAP-CAR technology license to include autoimmune indications.

4. Ongoing development of allogeneic SNAP-CAR NK cells for universal cancer treatment.

5. Presentation of research findings at major scientific conferences.

6. Upcoming Nasdaq compliance hearing on September 12 to address delisting determination.

Coeptis Therapeutics has secured $4.3 million from a Series A Preferred offering led by CJC Investment Trust, helmed by board member Christopher Calise. The Series A Preferred stock is convertible to common stock at $0.40 per share, with investors gaining a 6.45% equity interest in SNAP Biosciences and GEAR Therapeutics, new subsidiaries of Coeptis. Proceeds will repay outstanding obligations, support working capital, and fund general corporate purposes. CEO Dave Mehalick highlighted the financing's timing, aligning with anticipated significant milestones and strengthening the company's balance sheet and growth prospects.